List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120, E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9F, Airspace Designations and Reporting Points, dated September 10, 1998, and effective September 16, 1998, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AGL MN E5 Ada, MN [New]

Ada, Norman County Ada/Twin Valley Airport, MN
(Lat. 47°15′38″ N., long. 96°24′01″ W.)

That airspace extending upward from 700 feet above the surface within a 6.3-mile radius of the Norman County Ada/Twin Valley Airport.

* * * * *

Issued in Des Plaines, Illinois on November 24, 1998.

Maureen Woods,

Manager, Air Traffic Division.

[FR Doc. 98–32730 Filed 12–8–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 334

[Docket No. 78N–036L]

RIN 0910–AA01

Laxative Drug Products for Over-the-Counter Human Use; Partial Withdrawal of Proposed Amendment to the Tentative Final Monograph; Intent to Repropose

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of proposed rulemaking; withdrawal in part and intent to repropose.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing that part of the notice of proposed rulemaking that would have amended the tentative final monograph for over-the-counter (OTC) laxative drug products to include additional professional labeling for oral and rectal dibasic sodium phosphate/monobasic sodium phosphate (sodium phosphates) drug products. The agency intends to repropose the professional labeling for these products in a future issue of the **Federal Register**.

FOR FURTHER INFORMATION CONTACT: Gloria Chang, Center for Drug Evaluation and Research (HFD–560), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–2222.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of May 21, 1998 (63 FR 27886), FDA published an amendment to the tentative final monograph for OTC laxative drug products proposing to include additional general labeling and expanded professional labeling for oral and rectal sodium phosphates drug products. The agency proposed to expand the professional labeling for products containing sodium phosphates in § 334.80(b)(2) of the tentative final monograph for OTC laxative drug products (50 FR 2124 at 2157, January 15, 1985). The agency also proposed a new format using specific headings to make the proposed professional labeling information clearer and more readable. Interested persons were invited to submit written comments or objections by August 19, 1998.

The agency plans to further expand the professional labeling in proposed § 334.80(b)(2). This notice is to inform interested persons that the agency is withdrawing the proposed amendment to the OTC laxative tentative final monograph for professional labeling for products containing sodium phosphates in § 334.80(b)(2) and will be reproposing the professional labeling in a future issue of the **Federal Register**. Further, this partial withdrawal of the proposed amendment to the OTC laxative tentative final monograph does not affect the current marketing status of sodium phosphates drug products.

The agency has determined under 21 CFR 25.31(c) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This withdrawal notice is issued under authority of 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

Dated: December 1, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–32642 Filed 12–8–98; 8:45 am]

BILLING CODE 4160–01–F

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[MD055–3021b; FRL–6199–4]

Approval and Promulgation of Air Quality Implementation Plans; Maryland; Stage II Vapor Recovery Comparability Plan

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is taking direct final action on the State Implementation Plan (SIP) revision submitted by the State of Maryland. The revision concerns a plan which demonstrates that the emission reductions of volatile organic compounds (VOC) required in ozone attainment and marginal ozone nonattainment areas in Maryland are comparable to the reductions which would be achieved by Stage II vapor recovery (Stage II) in those same areas. EPA is proposing this revision to achieve reductions in the emissions of VOCs in the State of Maryland in accordance with the requirements of the Clean Air Act.

In the ''Rules and Regulations'' section of this **Federal Register**, EPA is approving the State's SIP submittal as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. A detailed rationale for the approval is set forth in the direct final rule. If EPA receives no adverse comments, EPA will not take further action on this proposed rule. If EPA receives adverse comments, EPA will withdraw the direct final rule and it will not take effect. EPA will address all public comments in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting on this action should do so at this time. This Stage II comparability plan allows Maryland to achieve VOC reductions.